Montanide ISA 51
Sponsors
National Cancer Institute (NCI), University of Southern California, David Peereboom
Conditions
MelanomaRecurrent Glioblastoma
Phase 2
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
CompletedNCT00059475
Start: 2003-04-30End: 2010-05-31Updated: 2012-10-23
Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma
CompletedNCT00080353
Start: 2004-03-31End: 2008-12-31Updated: 2012-06-14
Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma
TerminatedNCT00184067
Start: 2004-05-31End: 2009-09-30Updated: 2014-05-21
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
CompletedNCT04013672
Start: 2020-03-19End: 2022-02-16Updated: 2024-08-28